Consumer protection · from the 250-topic plan
Compounded quality signals: beyond-use dating, potency testing, and what good pharmacies publish
Once the license checks out and the classification is named, quality has a next layer — the signals separating careful compounding from adequate-on-paper: beyond-use dating (BUD) — the pharmacy-assigned use-by window that compounded products carry instead of manufacturer expiration, printed on every legitimate label; potency testing — third-party certificates of analysis showing the vial contains what the label claims, within tolerance; sterility and endotoxin practices — the USP-driven discipline behind injectables; and publication posture — because pharmacies proud of their testing say so, and the willingness to share a CoA is itself the strongest cheap signal in this file. The questions to ask, what the documents actually show (and honestly can't), the red flags, and where this site's open files sit — below. The permanent frame: testing verifies manufacturing quality, never approval — compounded products remain not FDA-approved.
Beyond-use dating, decoded
Manufactured drugs carry expiration dates from stability programs; compounded preparations carry beyond-use dates — assigned by the compounding pharmacy under USP frameworks, reflecting the preparation's category, conditions, and any supporting stability data, and typically shorter than manufactured-product expiries. What it means for you: the BUD on your vial's label is the use-by law of your supply — it interacts directly with vial math (a multi-dose vial outliving its BUD is waste scheduled in advance), with travel counting, and with shipment cadence (a program shipping 90 days of product with 45-day BUDs has made an arithmetic confession). The label check takes five seconds: a compounded injectable without a printed BUD is a walk-away — not a quirk, a violation of the basic discipline.
Potency testing and certificates of analysis
The question potency testing answers: does the vial contain the labeled amount of active ingredient, within tolerance? The document is a certificate of analysis (CoA) — ideally from an independent third-party lab — showing the tested lot, the assay method, and the result. What a good CoA tells you: this lot's identity and strength were verified by someone other than the seller. What it honestly can't: it's lot-specific (last month's certificate isn't this vial's), it isn't a clinical-outcomes claim, and it isn't approval — the certificate that travels is still the brand's. The maturity signal is cadence and access: pharmacies testing routinely and sharing on request sit in a different league from those testing never or sharing nothing, and “can I see a recent CoA for this preparation?” sorts the leagues in one message.
Sterility, briefly and honestly
Injectables are sterile preparations, which drags the whole USP sterile-compounding apparatus behind them — environmental controls, personnel practices, sterility and bacterial-endotoxin testing appropriate to the preparation's category and batch context. A consumer can't audit a cleanroom, and this file won't pretend otherwise; what a consumer can read is posture: a pharmacy that discusses its USP compliance, its testing practices, and (for 503B facilities) its FDA inspection history in plain language is running toward scrutiny, and the ones running away from the question have answered it. The historical footnote that built this entire regulatory structure — a national fungal-meningitis tragedy from contaminated compounded injections — is why none of this section is pedantry.
The asks, scripted
Four messages, sendable today, answers filed in the packet: “What pharmacy compounds my medication, and is it 503A or 503B?” (the classification file's opener); “What beyond-use dating will my vials carry, and how does that align with shipment size?” (the arithmetic-confession test); “Is potency tested by a third party, and can I see a recent CoA?” (the league sorter); “What's the pharmacy's USP compliance and testing posture?” (the plain-language test). Where this site's own universe stands, said with the usual candor: the audited anchor's pharmacy-identity file remains a posted open item on the NexLife page — these exact questions are the ones whose answers close it, and per the label, the rating rises only when they do. The file these questions close ↗
Red flags
The disqualifiers, field-manual grade: no BUD on the label; refusal to name the pharmacy (already fatal at check three); “proprietary” as the answer to testing questions; shipment sizes exceeding BUDs; CoAs that are stale, seller-generated, or for a different preparation waved as proof; and marketing that inflates testing into approval — “lab-tested” dressed up as “FDA-” anything, the exact conflation the manual exists to catch. One flag warrants questions; the label flag and the pharmacy-name flag warrant exits.
FAQ
What is a beyond-use date on compounded medication?
The pharmacy-assigned use-by window compounded preparations carry instead of manufacturer expiration — printed on every legitimate label, typically shorter than manufactured expiries, and a walk-away if absent.
What does a certificate of analysis prove?
That a specific lot's identity and potency were verified, ideally by a third party — lot-specific manufacturing verification, not a clinical claim and never approval.
How can I check a compounding pharmacy's quality?
Four asks: pharmacy name and classification, BUD-versus-shipment alignment, third-party CoA access, and USP compliance posture — plain-language answers signal quality; “proprietary” signals exit.
Does lab testing make compounded GLP-1s FDA-approved?
No — testing verifies manufacturing quality of a lot; approval and trial certificates remain with the brand products.
Sources
- USP compounding frameworks (BUD assignment, sterile-preparation standards).
- Certificate-of-analysis structure and third-party testing practice.
- Companion files: pharmacy verification, 503A/503B, vial math, field manual.